Search results
Results from the WOW.Com Content Network
The condition is also referred to as insulin-dependent diabetes, meaning exogenous insulin injections must replace the insulin the pancreas is no longer capable of producing for the body's needs. Type 1 is the most common form of diabetes in dogs and affects approximately 0.34% of dogs .
Side effects include weight gain and hypoglycemia. While the potential for hypoglycemia is less than for those on sulfonylureas, [citation needed] it is still a serious potential side effect that can be life-threatening. Patients on this medication should know the signs and symptoms of hypoglycemia and appropriate management.
The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection. [14] The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day.
The common side effect is low blood sugar. [5] Other side effects may include pain or skin changes at the sites of injection, low blood potassium, and allergic reactions. [5] Use during pregnancy is relatively safe for the baby. [5] Regular insulin can be made from the pancreas of pigs or cows. [2]
Common side effects include low blood sugar, problems at the site of injection, itchiness, and weight gain. [7] Other serious side effects include low blood potassium. [7] NPH insulin rather than insulin glargine is generally preferred in pregnancy. [8] After injection, microcrystals slowly release insulin for about 24 hours. [7]
Some side effects are hypoglycemia (low blood sugar), hypokalemia (low blood potassium), and allergic reactions. [6] Allergy to insulin affected about 2% of people, of which most reactions are not due to the insulin itself but to preservatives added to insulin such as zinc, protamine, and meta-cresol.
As a systematic review of studies comparing insulin detemir, insulin glargine, insulin degludec and NPH insulin did not show any clear benefits or serious adverse effects for any particular form of insulin for nocturnal hypoglycemia, severe hypoglycemia, glycated hemoglobin A1c, non-fatal myocardial infarction/stroke, health-related quality of ...
The onset of action of subcutaneous insulin glargine is somewhat slower than NPH human insulin. It is clear solution as there is no zinc in formula. [9] [better source needed] The biosimilar insulin glargine-yfgn (Semglee) was approved for medical use in the United States in July 2021, [10] and in the European Union in March 2018. [11]